✨ Free AI Report
Transgene SA: Key Facts, Business Model & Financial Analysis Read the overview below or get the full interactive report with Cyborg Score, analyst debate audio & saved-company playlists — free, no credit card.
Get Free Report →
Home Company Research Transgene SA
Company Research

Transgene SA: Business Overview, Financials & Competitive Analysis

Transgene is a biotechnology company focused on designing and developing targeted immunotherapies for cancer treatment, with a portfolio of viral vector-based immunotherapeutics. The company's proprietary myvac® platf...

Analyst-debate audio for Transgene SA

AskCyborg analysts argue the bull and bear cases for Transgene SA across 11 stress-tested dimensions. Listen on your commute -- faster than reading the 30-page report.

Play the free intro →
Free intro · Pro unlocks the full analyst debate
7/ 10Strong

Cyborg Score thesis

Transgene is a well-capitalized, clinical-stage immunotherapy leader with differentiated AI-driven personalized vaccine platform...

Read the full analyst-debate transcript →
Industry Biopharmaceuticals - Oncology Immunotherapy
3 named competitors
3 recent developments
11 analyst dimensions
Synthesized from analyst-debate stress-testing across 11 dimensions and hundreds of data points. Methodology →
Cyborg Score recalibrated: October 19, 2026
AI-Generated Research
30+ Page Report

Get the Latest Transgene SA Report

Up-to-date AI-powered research, analyst debate audio & saved-company playlists

Get Current Report Free
✓ No credit card required
or get it by email

Transgene SA Overview

Pro stress-test →

Transgene is a biotechnology company focused on designing and developing targeted immunotherapies for cancer treatment, with a portfolio of viral vector-based immunotherapeutics. The company's proprietary myvac® platform represents a paradigm shift in precision medicine, generating individualized virus-based immunotherapies that encode patient-specific mutations identified through AI capabilities provided by partner NEC.

Strategic Profile

Pro stress-test →

TG4050, the first individualized therapeutic vaccine based on the myvac® platform, is the company's lead asset with demonstrated proof of principle in patients for adjuvant treatment of head and neck cancers. The company has strategic collaborations with AstraZeneca, Merck KGaA, Pfizer, and NEC Corporation, positioning itself as a clinical-stage leader in individualized neoantigen therapeutic vaccines.

Competitive Landscape

Pro stress-test →

Transgene's portfolio includes TG4050 (individualized therapeutic vaccine), TG4001 (HPV vaccine), and BT-001 and TG6050 (oncolytic viruses). Key competitors in personalized neoantigen vaccines include BioNTech, CureVac, and other immunotherapy innovators. Transgene's differentiation lies in its clinically-validated myvac® platform and strong partnership ecosystem with major pharma players.

Industry Context

Transgene SA operates in Biopharmaceuticals - Oncology Immunotherapy.

Key facts

Founded: 1979 · Headquarters: Strasbourg, France · Employees: 160 · Market cap: $301M

What the AI analysts debated

AI-generated and not independently verified: selected findings from the multi-agent debate on Transgene SA.

  • Phase I data showed 100% Disease-Free Survival after minimum 2-year follow-up, providing clinical proof of principle for TG4050
  • Funding runway extended to early 2028 following €105 million capital raise in December 2025
+2 more AI-generated counter-arguments unlock with Pro. Read the full analyst debate →

Recent developments

Material events tracked by the AskCyborg corpus.

  • February 2026Appointed renowned cancer immunotherapy experts Antoine Italiano and Ignacio Melero to Scientific Advisory Board
  • January 2026Published Phase I data supporting TG4050's potential in preventing head and neck cancer relapse
  • +1 moreTrack every material event for Transgene SA as it happens. Explore monitoring →
Get alerted when Transgene SA has a new material development →

Named competitors

Pulled from the analyst-debate framework. Click any competitor to see their Cyborg Score.

mRNA-based neoantigen vaccinesBioNTech personalized oncology program→Immunotherapy programsCancer immunotherapy portfolio (collaboration partner)→Therapeutic vaccinesmRNA-based therapeutic vaccines→

Compare Transgene SA with another company

Pick any company in the AskCyborg corpus to see side-by-side Cyborg Scores and insights.

vs
Side-by-side opens in your AskCyborg account

Industry context

Transgene SA operates in Biopharmaceuticals - Oncology Immunotherapy. See how the rest of the sector scores on the Cyborg framework.

Browse Biopharmaceuticals - Oncology Immunotherapy research →
NEW · MCP server

Ask your AI assistant about Transgene SA

Install the free AskCyborg MCP server in Claude, Cursor, Cline, Continue, or Windsurf and ask any of these in-line:

“Compare Transgene SA and its top competitor on Cyborg Score”
“What did Transgene SA do this quarter?”
“Is Transgene SA a defensible business in 5 years?”
Install the MCP server (10 sec) →
Free, anonymous, no API key required

How AskCyborg research is made

⚔

AI analyst debate, not single-author opinion

Every report is generated by a panel of AI analysts arguing across 11 dimensions, so counter-arguments sit alongside the case. The debate is a reasoning process; it does not independently verify facts.

📊

Dated, not live

The Cyborg Score and recent developments reflect public sources as of the date shown and can miss or lag recent events. Check primary sources before relying on them.

🔗

Methodology open at /methodology

The framework, dimensions, and band breakdowns are documented. The Cyborg Score is an AI-generated opinion under that framework, not a credit rating or an investment recommendation.

🔒

Free tier is free

No credit card to read the research. Pro adds saved-company audio playlists, monitoring, audio briefings on demand, and PDF export for $39/mo annual.

Sources: public filings, regulatory data, and news flow, analysed by AI models. Read the methodology →

AI-generated research summary based on public sources; it may contain errors or omissions. Not investment advice. Not reviewed or endorsed by the companies covered. Report an error: legal@askcyborg.com · Terms of Service

Frequently asked questions

What does Transgene SA do?+
Transgene is a biotechnology company focused on designing and developing targeted immunotherapies for cancer treatment, with a portfolio of viral vector-based immunotherapeutics. The company's proprietary myvac® platf...
What is Transgene SA's Cyborg Score?+
Transgene SA has a Cyborg Score of 7/10 (Strong). The score synthesizes business model, financials, leadership, competitive position, technology, marketing, and ESG dimensions across hundreds of data points.
Who are Transgene SA's main competitors?+
Named competitors include mRNA-based neoantigen vaccines, Immunotherapy programs, Therapeutic vaccines. The full competitive landscape is in the AskCyborg report.
How can I get the full Transgene SA research report?+
Get the report plus analyst-debate audio at askcyborg.com -- no credit card required for preview access. Pro adds saved-company audio playlists and monitoring.
How current is the Transgene SA research?+
The Cyborg Score is recalibrated weekly. Recent developments are tracked continuously and surfaced in every report.

Track Transgene SA over time

Pro members get saved-company audio playlists, Cyborg Score recalibrations, and monitoring for material events across the AskCyborg corpus.

See Pro features
From $39/mo annual

Top-scored companies on AskCyborg

The strongest performers across the analyst-debate framework.

9Advantest Corporation9Anthropic9Apple Inc.9Applied Materials, Inc.9Arista Networks9Aritzia Inc.9ASML Holding N.V.9BAE Systems plc9Barrick Mining Corporation9Berkshire Hathaway Inc.